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Background: Persistent organic pollutants (POPs) are persistent in the environment after release from industrial
compounds, combustion productions or pesticides. The exposure of POPs has been related to various reproductive
disturbances, such as reduced semen quality, testicular cancer, and imbalanced sex ratio. Among POPs,
dichlorodiphenyldichloroethylene (4,4’-DDE) and polychlorinated biphenyls (PCBs) are the most widespread and
well-studied compounds. Recent studies have revealed that 4,4’-DDE is an antagonist of androgen receptor (AR).
However, the mechanism of the inhibition remains elusive. CB-153 is the most common congener of PCBs, while
the action of CB-153 on AR is still under debate.
Results: Molecular docking and molecular dynamics (MD) approaches have been employed to study binding
modes and inhibition mechanism of 4,4’-DDE and CB-153 against AR ligand binding domain (LBD). Several potential
binding sites have been detected and analyzed. One possible binding site is the same binding site of AR natural
ligand androgen 5α-dihydrotestosterone (DHT). Another one is on the ligand-dependent transcriptional activation
function (AF2) region, which is crucial for the co-activators recruitment. Besides, a novel possible binding site was
observed for POPs with low binding free energy with the receptor. Detailed interactions between ligands and the
receptor have been represented. The disrupting mechanism of POPs against AR has also been discussed.
Conclusions: POPs disrupt the function of AR through binding to three possible biding sites on AR/LBD. One of
them shares the same binding site of natural ligand of AR. Another one is on AF2 region. The third one is in a cleft
near N-terminal of the receptor. Significantly, values of binding free energy of POPs with AR/LBD are comparable to
that of natural ligand androgen DHT.
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Persistent organic pollutants (POPs), mainly from indus-
trial compounds, combustion productions or pesticides,
widely exist in the environment and are considered to be
potential endocrine disrupting chemicals (EDCs) [1-3].
These compounds are persistent in the environment after
releasing and transported to human body mainly through
contaminated foods [4]. Recent studies have linked POPs
exposures to reproductive disturbances, such as reduced* Correspondence: cxwangbjut@gmail.com
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reproduction in any medium, provided the orsemen quality, testicular cancer, and imbalanced sex
ratio [5-9]. Among POPs, dichlorodiphenyldichloroethylene
(4,4’-DDE) and polychlorinated biphenyls (PCBs) are the
most widespread and well-studied compounds. 4,4’-DDE is
the major metabolite of the widely used organochlorine in-
secticide dichlorodiphenyltrichloroethane (DDT) and has
been considered a good indicator of DDT exposure [10,11].
Among the 209 possible congeners of PCBs, 2,2’,4,4’,5,5’-
hexachlorobiphenyl (CB-153) is the most common one and
considered as a useful marker of PCBs [11,12]. The struc-
tures of 4,4’-DDE and CB-153 are illustrated in Figure 1.
These compounds display substantial structural similarities
with natural ligands of nuclear receptors (NRs) and thusThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Structures of 4,4’-DDE and CB-153.
Figure 2 Crystallographic structure of AR/LBD-DHT complex
(PDB ID: 1I37). The ligand DHT is represented with the licorice
model and the receptor LBD is represented with the newcartoon
model. AF2 and BF3 sites on LBD are displayed by the solvent
accessible surface area model.
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binding to the receptor [13,14].
Androgen receptor (AR) is a ligand activated transcrip-
tion factor belonging to nuclear receptor superfamily,
which is involved in regulation of various physiological
functions in human body, including cell growth, prolifera-
tion, and differentiation [15]. AR is a soluble protein
and AR-regulated gene expression is responsible for
the male reproductive system [16]. Its activity is regu-
lated by the binding of either androgens testosterone
or 5α-dihydrotestosterone (DHT). Like other members
of this family, AR consists of three functional domains,
the N-terminal transactivation domain, the central DNA
binding domain (DBD), and the C-terminal ligand binding
domain (LBD) that harbors a ligand-dependent transcrip-
tional activation function (AF2) [17]. AF2 region is a
hydrophobic cleft formed by the binding of agonist and
then binds with steroid receptor coactivator (SRC) family
of coactivators [16]. Since AR is considered as an effective
therapeutic target of prostate cancer, various compounds
have been designed as its inhibitors through directly bind-
ing to the ligand binding site avoiding natural ligands
binding [18]. A recent study also revealed that several
small molecules can bind to AF2 and then prevent the
transcriptional activation of AR [19]. Studies on other
members of the NR superfamily, such as estrogen recep-
tors (ER) and progesterone receptor (PR), also revealed
that the AF2 region on LBD is the binding site of some
antagonists [20-23]. Besides, another novel binding site,
binding function 3 (BF3), on the LBD have been identified
by a recent virtual screening study combined with bio-
chemical assays and X-ray crystallography [24,25] (see
Figure 2).
Indeed, 4,4’-DDE has been found to be an antagonist
of AR by numerous studies [14,26,27]. However, the
mechanism of the inhibition remains elusive. With re-
spect to CB-153, partial antagonistic properties on AR
were detected by Schrader et al. [28], whereas Bonefeld-
Jørgensen et al. found that CB-153 has no effect on AR
[29]. In the present work, we employed computational
approaches, molecular docking, molecular dynamics
(MD), and binding free energy calculation, to explore
detailed interactions between POPs and AR/LBD. Thebinding modes of 4,4’-DDE and CB-153 with AR/LBD
were identified with molecular docking method, followed
by long time MD simulations. The binding free energies
of AR/LBD-POPs complexes were also calculated and
compared with that of the natural ligand DHT. Based on




POPs were docked to AR/LBD based on crystal structure
taken from Protein Data Bank (PDB) with PDB entry 1I37
[17]. Autodocktools was used to prepare the systems and
the Gasteiger partial charges were assigned to the receptor
and ligands [30]. Dockings were performed with
AutoDock4.2 package [31]. Firstly, a box of 126 × 126 × 126
points was set with grid spacing 0.6 Å in each direction to
make sure there is enough space to fit the whole receptor
and also for the free rotation of ligands. The maximum
number of energy evaluations was set to 2.5 × 107. The
Lamarckian genetic algorithm (LGA) was used for the
sampling of complex conformations formed by ligand and
receptor. Other parameters were set to default. Then,
dockings were focused on predicted potential binding sites
with a grid number of the box 60 × 60 × 60 and smaller
grid spacing 0.375 Å. In docking calculations, single
bonds of ligands were treated as rotatable. Two and
one flexible torsions were defined for 4,4’-DDE and
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plexes were generated for each docking. Docking poses
were further refined by long time MD simulations.
Molecular dynamics simulations
MD simulations of AR/LBD and AR/LBD-ligand com-
plexes were carried out by GROMACS4.5.5 [32] with
GROMOS 43a1 force field [33]. Topologies of small
molecules were generated by using PRODRG server
[34]. Ligands were optimized using Gaussian 03 with
Hartree-Fock/6-31G* level and then mulliken charges
were reassigned to ligands for MD simulation [35,36].
Complexes were solvated by simple point charge (SPC)
water [37] in a cubic box extending at least 1.0 nm in all
directions from the solute. Five Cl- ions were added to
neutralize charges of the system. Long-range electro-
static interactions were calculated by the particle mesh
Evald (PME) method [38]. A cutoff radius of 1.0 nm for
van der Waals and short-range electrostatic interactions
was used. LINCS algorithm was used to constrain bond
lengths [39]. The temperature of the system was coupled
by using the velocity rescaling method [40] and the
pressure was coupled by using the Parrinello-Rahman
method [41]. The integration time step was set to be 2 fs.
First, the system was minimized for 1000 steps using the
steepest descent algorithm, followed by a 200 ps position
restrained molecular dynamics simulation. Then the sys-
tem was heated from 50 K up to 300 K by steps of 50 K
within 500 ps. Finally, a 30 ns simulation was carried out
for each system at a constant temperature of 300 K and a
constant pressure of 1 atm. Trajectories were analyzed by
using GROMACS software package and the figures of the
protein structures were created by VMD program [42].
MM/PBSA binding free energy
MM/PBSA (Molecular Mechanics/Poisson-Boltzmann
Surface Area) method [43], which combines molecular me-
chanics energy and continuum solvent models, has been
widely used for the free energy calculation of receptor-
ligand complexes [44,45]. The binding free energy, ΔGb, of
a ligand (L) binding to a receptor (R) forming a complex
RL is calculated as
ΔGb ¼ ΔEMM þ ΔGsolv−TΔS ð1Þ
where the first term, ΔEMM, gives the gas phase molecular
mechanics energy changes, which includes contributions
from the internal (ΔEint), electrostatic (ΔEelec), and van der
Waals (ΔEvdW) energies. The second term, ΔGsolv, provides
the changes of the solvation contributions consisting of the
polar solvation energy (ΔGPB,) and nonpolar solvation en-
ergy (ΔGSA). In the present work, the ΔGPB was calculated
by Adaptive Poisson-Boltzmann Solver (APBS) program
[46]. The grid spacing was set to 0.6 Å. The value of theexterior dielectric constant was set to 80, and the solute
interior dielectric constant was set to 4 [47]. The atomic
radii and charges were set according to those used in MD
simulations. The ΔGSA was determined by the solvent-
accessible surface area (SASA) approach, ΔGSA = γ ×
ΔSASA + β, with γ = 2.2 kJ/(mol nm2) and β = 3.84 kJ/mol
[43,48]. The quasi-harmonic analysis was performed to es-
timate the entropy change (−TΔS) of the system upon lig-
and binding [49]. In the method, the entropy is calculated
based on the all atom covariance matrix, which can be
obtained using a standard GROMACS utility applied to a
MD trajectory. The conformational entropy was estimated
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p
, with h is the Planck con-
stant, kB is the Boltzmann constant, T is the absolute
temperature, and λi are eigenvalues of the all-atom mass-
weighted covariance matrix of fluctuations δij ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃmimjp
xi− xih ið Þ xj− xj
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In this work, 1000 snapshots extracted from the last
10 ns simulations were used in the binding free energy
calculations of AR/LBD-POPs complexes.
Results and discussions
Docking of POPs to AR/LBD
DHT was redocked to AR/LBD with 100 independent
runs and docking results were clustered according to the
root mean square difference (RMS) with a cutoff value
0.2 nm. A large cluster (occupies 59% of total generations)
with the lowest value of binding energy (−45.6 kJ/mol)
was observed in which ligand binds to the natural ligand
binding site. In the second largest cluster (24%), DHT
binds to a region near the C-terminal of the receptor
(PBS3 in the following text) with a much larger value of
binding energy −30.4 kJ/mol. In remaining generations,
DHT arbitrarily binds on the surface of AR/LBD with
binding energies higher than −28.1 kJ/mol. Significantly,
the redocking of DHT to the natural ligand binding site
shows that the root mean square deviations (RMSD) of
ligand between predicted and crystallized is 0.12 nm. Both
the large energy gap (larger than 15 kJ/mol) between the
largest cluster (ligand binds to the natural ligand binding
site) and the others and the small RMSD value between
predicted and crystallized show that the using docking
methodology is satisfactory to the study. Then, 4,4’-DDE
and CB-153 were docked to AR/LBD with 100 independ-
ent runs for each case. 6 and 5 clusters were obtained for
4,4’-DDE and CB-153, respectively.
As shown in Figure 3A for 4,4’-DDE, the first three
clusters comprise the majority of the total docking
Figure 3 Docking results of POPs with AR/LBD. Generated 100
docking poses were clustered by root mean square (RMS) difference
with a cutoff value 0.2 nm for each case. The binding energy shown
in the x-axis is the mean value of each cluster. (A) is for 4,4’-DDE
and (B) is for CB-153. The chosen models are marked by PBS1-5
according to the positions of binding sites.
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cies of the first three clusters are 62%, 11%, and 24%
with average values of binding energy −31.4, -28.5,
and −21.4 kJ/mol, respectively. The remaining three
clusters consist of only one docking pose for each case.
Potential binding sites (PBSs) corresponding to the six
clusters are illustrated in Figure 4. PBS1 is a novel binding
pocket with cleft formed by H1, H3, H5 and H8. PBS2, a
hydrophobic pocket deep inside the receptor, is the same
binding site of the androgens like DHT, which is also the
binding site of antagonists. PBS3 is a pocket on the surfaceFigure 4 Predicted potential binding sites for POPs. Binding sites are d
cleft near the N-terminal of the receptor. PBS2 is also known as the bind si
pocket on the surface near the C-terminal of the receptor. PBS4 is in AF2 re
the right panel is obtained by rotating the left panel along z-axis with 180near the C-terminal comprised of β2 and H4. PBS4 is in
the AF2 region, a hydrophobic surface for the binding of
coactivators. PBS5 is on the surface of helix 7 and 10. The
last potential binding site, PBS5’, is quite near to the PBS5
with a similar value of binding free energy. We consider
these two possible bind sites as the same one.
Figure 3B shows the cluster composition for CB-153
docking poses. Remarkably, the same five potential bind-
ing sites are also observed for CB-153. In Figure 3B,
each cluster is marked according to the location of the
potential binding site shown in Figure 4. Similar to the
case of 4,4’-DDE, the cluster corresponding to PBS1 is
the largest one with a occupancy of 60%. Differently, the
PBS with the lowest binding free energy is PBS2, the nat-
ural ligand binding site. The occupancies of PBS4 and
PBS5 are larger than those for 4,4’-DDE.
To obtain more favorable binding modes and also the
inhibition mechanism of POPs with AR/LBD, docking
pose with the lowest binding free energy in each cluster
has been chosen for further MD study and MM/PBSA
analysis.
Conformational stability of Simulations
Ten MD runs with 30 ns were carried out on selected
AR/LBD-POPs complex structures. In order to investi-
gate the stability of the receptor after ligand binding,
we calculated temporal evolutions of backbone RMSD
of the receptor. As shown in Figure 5A for predicted
AR/LBD-4,4’-DDE complexes, backbone-RMSDs for
the first three runs reach stable values after about 3 ns
and stay around 0.2 nm in the remaining simulations. The
value of backbone-RMSD of model 4 keeps rising to
0.25 nm in the first 10 ns and returns back to around
0.2 nm at the end of the simulation. For the model 5, the
value of backbone-RMSD increases rapidly up to 0.21 nm
after the simulation. When the equilibrium is reached, the
values of backbone-RMSD are around 0.25 nm, which is
larger than other models. Figure 5B shows the temporaletermined by the docking study between AR/LBD and POPs. PBS1 is a
te of the natural ligand, which is deep inside the receptor. PBS3 is a
gion. PBS5 is on the surface of between H7 and H10. The figure on
degrees.
Figure 5 Time evolutions of backbone RMSD of AR/LBD, based
on 30 ns MD simulation for each AR/LBD-ligand complex. (A)
for the three binding modes of 4,4’-DDE with LBD and (B) for the
case of CB-153.
Figure 6 Time evolutions of ligand RMSD, calculated by
superimposing backbone atoms of the receptor AR/LBD. (A) for
AR/LBD-4,4’-DDE complexes and (B) for AR/LBD-CB-153 complexes.
The corresponding time evolutions of receptor RMSD are shown in
Figure 5.
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AR/LBD-CB-153 complexes. Similar to that observed in
Figure 5A, the values of backbone-RMSD of all runs con-
tinue rise in the first 3 ns. Then, the values of backbone-
RMSD for PBS1, PBS2, PBS4, and PBS5 keep rising and
fluctuate around 0.23 nm in the remaining simulations.
The backbone-RMSD for PBS3 reaches stable with a
smaller value around 0.2 nm.
To investigate the stability of ligands in binding sites,
we calculated RMSDs of ligands as a function of time
by superimposing backbone atoms of the receptor. As
shown in Figure 6A for AR/LBD-DDE complexes, the
RMSD of 4,4’-DDE in PBS1 rapidly increases up to 0.3 nm
and then keep stable in the whole simulation. For the case
of PBS2, the value of RMSD slowly rises to 0.4 nm in the
first 5 ns and keeps stable for about 5 ns, followed by a de-
crease to 0.3 nm. At 16 ns, the RMSD of 4,4’-DDE rises
again reaching up to 0.4 nm and keeps stable in the
rest of the simulation. The whole RMSD evolution displays
an indented curve which dues to the local rearrangement
after ligand binding. Significantly, the RMSD of 4,4’-DDE
in PBS3 rises quickly up to a relatively large value of
0.8 nm in the first 2 ns and keeps stable for about 5 ns.
Then it rises again and fluctuates around a value of 1.0 nm
in the remaining time. The ligand RMSDs for PBS4 and
PBS5 rise up to a value of 0.7 nm and keep stable in whole
simulations. The large values of RMSD observed in model
3, 4, and 5 indicate that new binding patterns in thosebinding sites have been achieved during MD simulations.
The temporal evolutions of ligand RMSD in AR/LBD-CB-
153 complexes are shown in Figure 6B. Similar to that ob-
served for 4,4’-DDE, the values of ligand RMSD for PBS1
and PBS2 increase up to 0.2 nm and 0.3 nm, respectively,
in the first 5 ns and then they keep stable in the following
25 ns simulations. Relative large values of RMSD have
been observed after several nanosecond simulations for
PBS3 and PBS5. Differently, an indented curve was ob-
served for the evolution of ligand RMSD when CB-153
binds to PBS4. The equilibrium value of ligand RMSD for
PBS4 is very small with a value around 0.1 nm. Overall, li-
gands binding in PBS1 and PBS2 are quite stable during
MD simulations, while large motions were observed when
ligands are located at PBS3, PBS4, and PBS5, which are on
the surface of the receptor.
Binding free energy
The binding free energies of predicted AR/LBD-POPs
complexes were estimated by MM/PBSA approach,
which has been widely used on protein-ligand complexes
and compared with experimental measurements [45,50].
The values are reported in Table 1. For 4,4’-DDE, the
binding mode of PBS1 is the most stable one with a
binding free energy value of −198.9 kJ/mol, which is
lower than that of the mode binding to natural ligand
binding site PBS2 (−177.0 kJ/mol). On the contrary, for
Table 1 Binding free energies of 4,4’-DDE, CB-153, and DHT with AR/LBD
Binding mode ΔEelec ΔEvdW ΔGPB ΔGSA -TΔS ΔGb
4,4’-DDE/PBS1 −18.8(7.8) −206.2(9.5) 22.9(3.18) −10.9(0.5) 14.1 −198.9
4,4’-DDE/PBS2 −3.9(1.8) −196.8(9.1) 9.4(1.9) −11.2(0.5) 25.5 −177.0
4,4’-DDE/PBS3 −10.9(6.1) −119.7(16.8) 11.8(6.7) −6.4(0.9) 29.6 −95.6
4,4’-DDE/PBS4 −2.1(2.5) −147.2(12.4) 8.4(2.2) −8.3(0.7) 20.4 −128.8
4,4’-DDE/PBS5 −4.0(4.9) −120.0(20.4) 8.8(2.7) −6.2(1.4) 23.9 −97.5
CB-153/PBS1 −5.6(5.8) −164.8(9.8) 25.7(4.2) −9.1(0.6) 11.0 −142.8
CB-153/PBS2 −4.3(2.2) −197.8(9.2) 10.2(1.9) −11.3(0.5) 10.4 −192.9
CB-153/PBS3 −2.8(4.5) −121.8(18.9) 13.3(2.5) −6.6(1.0) 14.6 −103.3
CB-153/PBS4 0.1(0.8) −131.2(8.8) 7.2(2.1) −8.2(0.6) 10.4 −121.7
CB-153/PBS5 −4.3(3.8) −130.3(15.0) 12.9(3.5) −7.2(1.3) 8.2 −120.7
DHT/PBS2 −41.8(12.1) −195.5(9.9) 12.6(11.5) −10.5(0.5) 26.2 −209.0
The unit is in kJ/mol and values in parentheses are standard deviations of average.
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(−192.9 kJ/mol) is visibly lower than that at PBS1
(−142.8 kJ/mol). Besides, low values of binding free en-
ergy were also observed for the two ligands (−128.8 kJ/mol
for 4,4’-DDE and −121.7 kJ/mol for CB-153) when they
bind to PBS4. However, the binding free energy values of
both ligands at PBS3 are significantly larger than those
binding in previous binding sites. For the last potential
binding site, PBS5, the value of binding free energy for
4,4’-DDE (−97.5 kJ/mol) is comparable to that of PBS3 and
the value for CB-153 (−120.7 kJ/mol) is comparable to that
of PBS4. According to the results of binding free energy, it
comes out that 4,4’-DDE prefers to bind to PBS1 while
CB-153 prefers to bind to PBS2. It is noted that PBS2 is
the binding site for natural ligands, and a low binding free
energy was observed when ligands bind to this binding site.
Interestingly, we also found that the binding free energies
of ligands binding in PBS1 are comparable to or even
lower than those for PBS2, indicating a possible alternative
binding site through which POPs display their disrupting
effects. Besides, low values of binding free energy were
also observed when POPs bind to PBS4 which corre-
sponds to AF2 region, suggesting another possible inhib-
ition mechanism.
An advantage of MM/PBSA approach is that it allows
us to assess the contributions of each term in the free en-
ergy function (Eq. 1). The contributions of the gas-phase
molecular mechanics energy and the solvation compo-
nents are listed in Table 1. Since structures (monomers or
complex) used for MM/PBSA calculations are derived
from the same MD trajectories, the contributions of in-
ternal term of the molecular mechanics (ΔEint) are set to
zero. Favorable contributions from electrostatic term
(ΔEelec) have been observed for all binding modes, with
values of −2.1 ~ −18.9 and −0.1 ~ −5.6 kJ/mol for 4,4’-
DDE and CB-153, respectively. Significantly, values of vander Waals (ΔEvdW) energy are from −119.7 to −206.2 kJ/
mol for 4,4’-DDE and from −121.8 to −197.8 for CB-153,
indicating large favorable contributions to the final bind-
ing free energies (ΔGb). The results are consistent with
the hydrophobic character of the ligands. At variance, un-
favorable contributions were detected for polar solvation
energy (ΔGPB). Values of ΔGPB for both ligands binding in
PBS1 are larger than those binding to the other binding
sites; this might be due to rearrangements of some
charged residues in PBS1 after the ligand binding (also see
below). Low values of nonpolar solvation energy (ΔGSA),
ranging from −9.1 to −11.3 kJ/mol, were observed for both
ligands when they bind to PBS1 or PBS2. While higher
values of ΔGSA were detected when POPs bind to other
possible bind sites, attributing to the smaller interface be-
tween ligands and receptor in these binding modes. The
entropic results show that the configurational entropic
component is unfavorable to the ligand binding for all
binding modes.
Since natural ligand binding site (PBS2) has been con-
sidered as one of the potential binding sites of POPs, for
comparison, the binding free energy of the receptor with
the natural ligand DHT was also calculated based on the
crystal structure of complex AR/LBD-DHT with PDB
ID: 1I37 [17]. 10 ns MD simulation was performed with
the same setting described in the Method Section. 500
snapshots taken from the last 5 ns stable trajectory were
used for the MM/PBSA calculation. The results are also
listed in Table 1. The binding free energy of DHT to AR/
LBD is −209.0 kJ/mol which is slightly lower than those of
4,4’-DDE (−177.0 kJ/mol) and CB-153 (−192.9 kJ/mol).
The detailed energetic components show that the lower
binding free energy of DHT is mainly due to the electro-
static term (ΔEelec). This is in agreement with the evidence
of several hydrogen bonds forming between DHT and
AR/LBD in the crystal structure [17].
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To investigate detailed interactions between POPs and the
receptor, the structure of each binding mode was averaged
over last 100 ps from MD simulation. In Figure 7, we illus-
trate the three most possible binding modes (PBS1, PBS2,
and PBS4) for each ligand. The other two possible binding
modes for each case are reported in Additional file 1:
Figure S1. Contacting residues of the ligand were determined
by LIGPLOT program with a cutoff value of 0.4 nm [51].
It is found that POPs can bind to PBS1 with high af-
finities, especially for 4,4’-DDE. As shown in Figure 7,
the binding pocket of 4,4’-DDE/PBS1 is mainly formed
by the hydrophobic residues including Pro682, Val715,
Leu744, Met745, Val748, and Met749. Additionally, two
positive charged residues, Arg752 and Lys808, also inter-
act with the ligand. Interestingly, Lys808 forms a cation-
π interaction with a benzyl group of DDE, which might
be important for the binding of 4,4’-DDE. For the case
of CB-153/PBS1, the ligand is inserted into the cleft with
ligand-contacting residues Ala748, Trp751, Phe804, and
Lys808. A cation-π interaction between Lys808 and a
benzyl group of CB-153 was also observed. Besides, a π-
π packing is formed between Phe804 and the other ben-
zyl group of CB-153 (also see Figure 7D). As shown in
Figure 3, PBS1 is far away from AF2 region. The ligands
binding to this site might disrupt the receptor’s functionFigure 7 Detailed interactions of predicted binding modes of POPs w
MD run. (A), (B) and (C) correspond to 4,4’-DDE binding to AR/LBD on PB
binding to AR/LBD on PBS1, PBS2 and PBS4, respectively. Contact residues
cutoff value 0.4 nm. Both contact residues and POPs are represented withthrough some allosteric effects, which needs further ex-
perimental confirmation.
In PBS2, both 4,4’-DDE and CB-153 are buried inside
the hydrophobic cavity formed by H3, H5, H11, H12,
and β1. The binding pocket of 4,4’-DDE/PBS2 consists
of four hydrophobic residues, Leu704, Met742, Phe764,
and Met780. Interestingly, almost the same hydrophobic
pocket was found for CB-153/PBS2 which is formed by re-
sides, Leu704, Met742, Phe764, Met780, and Leu873. Be-
sides that, the orientations of the two ligands in the
binding pocket are similar with one benzyl group inserting
between Phe764 and Met742 and the other one toward
the Met780. Since DHT acts as an agonist via binding to
PBS2, the comparison of binding modes between POPs
and DHT could provide clues to understanding of the in-
hibitory mechanism of 4,4’-DDE and CB-153 against AR.
The detailed interactions between DHT and AR/LBD and
the comparison with POPs can be found in supplementary
material (Additional file 1: Figure S2), revealing different
binding patterns of DHT and POPs corresponding to their
opposite behaviors agonist AR.
Different to the above two binding sites, PBS4 is a
hydrophobic binding pocket formed by H3, H5, and
H12 on the surface of the receptor (also see Figure 2 and
Figure 4). Detailed contacts of ligands with the receptor
are also displayed in Figure 7. 4,4’-DDE binds to PBS4 byith AR/LBD, obtained by averaging over the last 100 ps of each
S1, PBS2 and PBS4, respectively. (D), (E) and (F) correspond to CB-153
(marked in the figure) are determined by the LIGPLOT program with a
the licorice model.
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http://www.biomedcentral.com/1472-6807/13/16anchoring one benzyl group between Val716 and Met894
and the other between Met894 and Ile898. For CB-153 as
shown in Figure 7F, interactions are mainly focused on
Val716 on H3 and Met734 on H5. As illustrated in the sec-
tion of Introduction, AF2 region has been identified to be a
binding site of some antagonists for AR as well as some
other members of NR. Since PBS4 is in the AF2 region cor-
responding to the interface of AR with coactivators, binding
of POPs to this binding site would interrupt directly inter-
actions between AR and its coactivators.
Conclusions
In the present study, molecular docking and MD simula-
tion were performed to probe the binding modes of two
most widespread POPs, 4,4’-DDE and CB-153, with AR/
LBD. Several potential binding sites including natural lig-
and binding site (PBS2) and AF2 (PBS4) have been detected
and analyzed. MD simulations of the docking poses have
allowed us to show that POPs form stable complexes with
AR/LBD. The binding free energies of POPs and an agonist
DHT with AR/LBD were estimated using MM/PBSA ap-
proach. The results reveal that the binding free energies of
POPs binding to PBS2 are comparable with those of AR/
LBD-DHT complex. Significantly, a novel potential binding
site PBS1 possesses similar binding free energies to those of
PBS2 with POPs binding. Our study illustrated the endo-
crine disrupting mechanism of POPs, which would also be
useful for designing new drugs with AR as a target.
Additional file
Additional file 1: Figure S1. Detailed interactions of predicted binding
modes of POPs with AR/LBD at PBS3 and PBS5, obtained by averaging
over the last 100 ps of each MD run. Figure S2. Binding mode of DHT
with AR/LBD and the comparison with POPs.
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